Physicians' Academy for Cardiovascular Education

Managing patients with HCM and HF: what’s new in the therapeutic landscape?

10' education - July 3, 2023 - Iacopo Olivotto, MD - Florence, Italy

Video navigation menu

  • Heart failure in HCM occurs in two contexts 0:23
  • Cardiac myosin inhibitors 1:31
  • The EXPLORER-HCM trial 3:09
  • Phase 2 study with aficamten 7:07
  • Treatment options for symptomtatic LVOT obstruction  7:42
  • Heart failure in HCM disease progression and ongoing studies  10:26

What was observed in the VALOR-HCM trial with regard to (heart failure) symptoms in patients with obstructive HCM? Compared to placebo, treatment with the myosin inhibitor mavacamten...

  • A. did not result in a change in NYHA class
  • B. resulted in a higher percentage of patients who improved ≥1 NYHA class
  • C. resulted in a higher percentage of patients who improved ≥1 NYHA class, but not of ≥2 NYHA class
  • D. resulted in a higher percentage of patients who improved ≥1 NYHA class and ≥2 NYHA class
Show the correct answer.


Show transcript

Educational information

This lecture by Iacopo Olivotto was part of the EBAC-accredited symposium "Hypertrophic cardiomyopathy and heart failure: exploring new options" at ESC Heart Failure in Prague, Czech Republic.


Prof. Iacopo Olivotto is Head of the Cardiology Unit at Meyer University Children Hospital and Professor of Cardiovascular Medicine at the University of Florence, Italy. His main clinical and research interests include various aspects of cardiomyopathies, with special focus on hypertrophic cardiomyopathy.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Bristol Myers Squibb.

Find here the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: